HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Lung cancers with Human Epidermal growth factor 2 (HER2, ERBB2) mutations are driven by oncogenic alterations.
• HER2-targeted therapies are emerging as effective treatments for these specific lung cancer subtypes.
• Limited data exists on the differential sensitivity of various HER2-mutant lung cancers to targeted agents.

Observation:

• A patient with HER2-mutant lung cancer presented with a specific 12 base pair insertion (YVMA, p.A775_G776insYVMA) in the HER2 gene.
• The patient experienced a prolonged disease course and a sustained partial response to afatinib treatment.
• This specific mutation, YVMA insertion in exon 20, represents the most common variant of HER2 mutations in lung cancer.

Findings:

• Afatinib demonstrated clinical activity in a patient with HER2-mutant lung cancer harboring the YVMA exon 20 insertion.
• The study highlights the therapeutic potential of afatinib for a prevalent subtype of HER2-driven lung cancer.

Implications:

• Afatinib can be considered a viable targeted therapy option for patients with HER2 exon 20 YVMA insertion-mutant lung cancers.
• Further clinical investigations are warranted to confirm the efficacy and safety of afatinib in a broader patient cohort with this specific mutation.
• This research contributes to a better understanding of personalized medicine approaches in non-small cell lung cancer treatment.